The authors demonstrated that the MUC1-C inhibitor GO-203 could severely deplete active β-catenin expression and survivin expression, increasing the sensitivity of AML cells to cytarabine treatment. The gene discussed is BIRC5; the disease is acute myeloid leukemia.